TransCode Therapeutics Inc [RNAZ] stock prices are up 3.30% to $0.71 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The RNAZ shares have gain 4.59% over the last week, with a monthly amount drifted -2.86%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 20, February 2024, TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic. In a post published today on Yahoo Finance, TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, reported publication of United States Patent Application titled, “Nanoparticles and Template Directed RIG-I Agonist Precursor Compositions and Uses Thereof For Cancer Therapy“ (Pub. No.: US 2024/0042070 A1; Pub. Date: February 8, 2024).
From an analyst’s perspective:
The stock price of TransCode Therapeutics Inc [RNAZ] has been fluctuating between $0.56 and $440.00 over the past year. TransCode Therapeutics Inc [NASDAQ: RNAZ] shares were valued at $0.71 at the most recent close of the market.
Analyzing the RNAZ fundamentals
Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.6821 points at the first support level, and at 0.6541 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.7411, and for the 2nd resistance point, it is at 0.7721.
TransCode Therapeutics Inc [RNAZ] reported earnings per share of -$67.2 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$60/share, meaning a difference of -$7.2 and a surprise factor of -12.00%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$131.6 per share as compared to estimates of -$135.6 per share, a difference of $4 representing a surprise of 2.90%.
Ratios To Look Out For
It’s worth pointing out that TransCode Therapeutics Inc [NASDAQ:RNAZ]’s Current Ratio is 1.67. On the other hand, the Quick Ratio is 1.67, and the Cash Ratio is 0.05.
Transactions by insiders
Recent insider trading involved Dudley Robert Michael, Chief Executive Officer, that happened on Sep 28 when 98000.0 shares were purchased. Chief Financial Officer, Fitzgerald Thomas A completed a deal on Sep 28 to buy 49350.0 shares. Meanwhile, Chief Executive Officer Dudley Robert Michael bought 12000.0 shares on Jun 21.
